Molecular Aspects of Platinum-DNA Interactions

  • Kenneth M. Comess
  • Stephen J. Lippard
Chapter
Part of the Topics in Molecular and Structural Biology book series (TMSB)

Abstract

The intracellular chemistry and biological processing of platinum anticancer drugs have been subjects of interest following the discovery of antitumour activity for cis-diamminedichloroplatinum(II) (cis-DDP, or cisplatin, Figure 5.1) (Rosenberg et al. 1965). Although several analogous platinum compounds have received FDA approval in the USA or are in clinical trials (see next chapter), a greater understanding of the molecular mechanism of action of platinum anticancer drugs is essential for the rational design of compounds with broader therapeutic specificity and reduced side-effects. At present, cisplatin is used in the USA for the treatment of metastatic testicular tumours, metastatic ovarian tumours, various head and neck tumours, and advanced bladder cancer. It is particularly effective against testicular cancer, which is the most common form of the disease among males in the 21- to 35-year-old age group. The orderly development of cis-DDP-based combination chemotherapy regimens has led to a present cure rate for testis cancer of approximately 95 per cent (Fox and Loehrer, 1991).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Admiraal, G., Alink, M., Altona, C., Dijt, F. J., van Garderen, C. J., de Graaff, R. A. G. and Reedijk, J. (1992). Conformation of Pt(dien)[d(ApGpA)-N7(2)] in the solid state and in aqueous solution, as determined with single-crystal X-ray diffraction and high-resolution NMR spectroscopy in solution. J. Am. Chem. Soc., 114, 930–938CrossRefGoogle Scholar
  2. Akaboshi, M., Kawai, K., Maki, H., Akuta, K., Ujeno, Y. and Miyahara, T. (1992). The number of platinum atoms binding to DNA, RNA and protein molecules of HeLa cells treated with cisplatin at its mean lethal concentration. Jap. J. Cancer Res., 83, 522–526CrossRefGoogle Scholar
  3. Anderson, K. S. (1979). Platinum(II) complexes generate frameshift mutations in test strains of Salmonella typhimurium. Mutation Res., 67, 209–214CrossRefGoogle Scholar
  4. Andrews, P. A. and Howell, S. B. (1990). Cellular pharmacology of cisplatin: Perspectives on mechanisms of acquired resistance. Cancer Cells, 2, 35–43PubMedGoogle Scholar
  5. Appleton, T. G., Hall, J. R., Neale, D. W. and Thompson, C. S. M. (1990). Reactions of the cis-diamminediaquaplatinum(II) cation with 2-aminomalonic acid and its homologues, aspartic and glutamic acids. Rearrangements of metastable complexes with carboxylate-bound ligands to N,0-chelates and formation of di- and trinuclear complexes. Inorg. Chem., 29, 3985–3990CrossRefGoogle Scholar
  6. Appleton, T. G., Hall, J. R. and Ralph, S. F. (1986). 15N and 195Pt N.M.R. study of the effect of chain length, n, on the reactions of amino acids, +NH,(CH2)„CO2 (n = 1, 2, 3), with platinum(II) ammine complexes. Aust. J. Chem., 39, 1347–1362Google Scholar
  7. Arpalahti, J. (1990). Kinetics for pH-dependent complexation of aquated cisdiammineplatinum(II) with inosine and 1-methylinosine. Inorg. Chem., 29, 4598–4602CrossRefGoogle Scholar
  8. Arpalahti, J. and Lehikoinen, P. (1990). Kinetics of complexation of aquated Pt(II)(dien) with inosine and 1-methylinosine as a function of pH. Inorg. Chem., 29, 2564–2567CrossRefGoogle Scholar
  9. Arpalahti, J. and Lippert, B. (1990). Coordination of aquated cis-platinum(II) diamines to purine nucleosides. Kinetics of complex formation. Inorg. Chem., 29, 104–110CrossRefGoogle Scholar
  10. Bancroft, D. P., Lepre, C. A. and Lippard, S. J. (1990). i95Pt NMR kinetic and mechanistic studies of cis- and trans-diamminedichloroplatinum(II) binding to DNA. J. Am. Chem. Soc., 112, 6860–6871Google Scholar
  11. Banerjee, S. K., Borden, A., Christensen, R. B., LeClerc, J. E. and Lawrence, C. W. (1990). SOS-dependent replication past a single trans-syn T-T cyclobutane dimer gives a different mutation spectrum and increased error rate compared with replication past this lesion in uninduced cells. J. Bacteriol., 172, 2105–2112PubMedPubMedCentralGoogle Scholar
  12. Banjar, Z. M., Hnilica, L. S., Briggs, R. C., Stein, J. and Stein, G. (1984). cis- and trans-Diamminedichloroplatinum(II)-mediated crosslinking of chromosomal non-histone proteins to DNA in HeLa cells. Biochemistry, 23, 1921–1926Google Scholar
  13. Basu, A., Teicher, B. A. and Lazo, J. S. (1990). Involvement of protein kinase C in phorbol ester-induced sensitization of HeLa cells to cis-diamminedichloroplatinum(II). J. Biol. Chem., 265, 8451–8457PubMedGoogle Scholar
  14. Basu, A. K. and Essigmann, J. M. (1988). Site-specifically modified oligodeoxynucleotides as probes for the structural and biological effects of DNA-damaging agents. Chem. Res. Toxicol, 1, 1–18PubMedCrossRefGoogle Scholar
  15. Baudin, F., Romby, P., Romaniuk, P. J., Ehresmann, B. and Ehresmann, C. (1989). Crosslinking of transcription factor TFIIIA to ribosomal 5S RNA from X. laevis by trans-diamminedichloroplatinum(II). Nucleic Acids Res., 17, 10035–10046PubMedPubMedCentralCrossRefGoogle Scholar
  16. Bellon, S. F., Coleman, J H and Lippard, S. J. (1991). DNA unwinding produced by site-specific intrastrand crosslinks of the antitumor drug cis-diamminedichloro-platinum(II). Biochemistry, 30, 8026–8035PubMedCrossRefGoogle Scholar
  17. Berners-Price, S. J. and Kuchel, P. W. (1990a). Reaction of cis- and trans- [PtC12(NH3)2] with reduced glutathione inside human red blood cells, studied by H and 15N-{1H) DEPT NMR. J. Inorg. Biochem., 38, 327–345Google Scholar
  18. Berners-Price, S. J. and Kuchel, P. W. (1990b). Reaction of cis- and trans[PtC12(NH3)2] with reduced glutathione studied by 1H, 13C, 195Pt and 15N-{1H} DEPT NMR. J. Inorg. Biochem., 38, 305–326Google Scholar
  19. Bodenner, D. L., Dedon, P. C., Keng, P. C., Katz, J. C. and Borch, R. F. (1986). Selective protection against cis-diamminedichloroplatinum(II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate rescue. Cancer Res., 46, 2751–2756PubMedGoogle Scholar
  20. Bohr, V. A. (1991). Gene specific DNA repair. Carcinogenesis, 12, 1983–1992PubMedCrossRefGoogle Scholar
  21. Bohr, V. A., Nairn, R. S., Wassermann, K., Jones, J. C., Zhen, W. and May, A. (1991). Studies of preferential DNA repair and strand specificity of DNA repair in the DHFR gene after treatment of hamster cells with UV and chemotherapeutics. Proc. Am. Assoc. Cancer Res., 32, 4Google Scholar
  22. Bowler, B. E. and Lippard, S. J. (1986). Modulation of platinum antitumor drug binding to DNA by linked and free intercalators. Biochemistry, 25, 3031–3038PubMedCrossRefGoogle Scholar
  23. Bradley, L. J. N., Yarema, K. J., Lippard, S. J. and Essigmann, J. M. (1993). Mutagenicity and genotoxicity of the major DNA adduct of the antitumor drug cis-diamminedichloroplatinum(II). Biochemistry, 32, 982–988PubMedCrossRefGoogle Scholar
  24. Bridges, B. A. and Woodgate, R. (1985). Mutagenic repair in Eschericia coli. RecA and umuC,D gene products act at different steps in UV mutagenesis. Proc. Natl Acad. Sci. USA, 82, 4193–4197PubMedPubMedCentralCrossRefGoogle Scholar
  25. Bruhn, S. L., Pil, P. M., Essigmann, J. M., Housman, D. E. and Lippard, S. J. (1992). Isolation and characterization of human cDNA clones encoding a high mobility group box protein that recognizes structural distortions to DNA caused by binding of the anticancer agent cisplatin. Proc. Natl Acad. Sci., USA, 89, 2307–2311PubMedPubMedCentralCrossRefGoogle Scholar
  26. Bruhn, S. L., Toney, J. H. and Lippard, S. J. (1990). Biological processing of DNA modified by platinum compounds. Prog. Inorg. Chem., 38, 477–516CrossRefGoogle Scholar
  27. Bubley, G. J., Ashbumer, B. P. and Teicher, B. A. (1991). Spectrum of cisdiamminedichloroplatinum(II) induced mutations in a shuttle vector propagated in human cells. Mol. Carcinogen., 4, 397–406CrossRefGoogle Scholar
  28. Buchanan, R. M. and Gralla, J. D. (1990). Cisplatin resistance and mechanism in a viral test system: SV40 isolates that resist inhibition by the antitumor drug have lost regulatory DNA. Biochemistry, 29, 3436–3442PubMedCrossRefGoogle Scholar
  29. Burnout, D., Daune, M. and Fuchs, R. P. P. (1987). Spectrum of cisplatin-induced mutations in Escherichia coli. Proc. Natl Acad. Sci. USA, 84, 3758–3762CrossRefGoogle Scholar
  30. Burnout, D., Gauthier, C., Chottard, J. C. and Fuchs, R. P. P. (1990). Single d(ApG)/cis-diamminedichloroplatinum(II) adduct-induced mutagenesis in Escherichia coli. Proc. Natl Acad. Sci. USA, 87, 6087–6091CrossRefGoogle Scholar
  31. Calabresi, P. and Parks, J. R. E. (1985). In Gilman, A. G., Goodman, L. S., Rall, T. W. Murad, F. (Eds.), Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 7th edn. Macmillan, New York, pp. 1290–1291Google Scholar
  32. Canon, J.-L., Humblet, Y. and Symann, M. (1990). Resistance to cisplatin: How to deal with the problem? Eur. J. Cancer, 26, 1–3PubMedCrossRefGoogle Scholar
  33. Caradonna, J. P., Lippard, S. J., Gait, M. J. and Singh, M. (1982). The antitumor drug cis-[Pt(NH3)2C12] forms an intrastrand d(GpG) crosslink upon reaction with [d(ApGpGpCpCpT)]2. J. Am. Chem. Soc., 104, 5793–5795CrossRefGoogle Scholar
  34. Cariello, N. F., Swenberg, J. A. and Skopek, T. R. (1992). In vitro mutational specificity of cisplatin in the human hypoxanthine guanine phosphoribosyltransferase gene. Cancer Res., 52, 2866–2873PubMedGoogle Scholar
  35. Chao, C.-K., Huang, S.-L., Lee, L.-Y and Lin-Chao, S. (1991). Identification of inducible damage-recognition proteins that are overexpressed in HeLa cells resistant to cis- diamminedichloroplatinum(II). Biochem. J., 277, 875–878PubMedPubMedCentralCrossRefGoogle Scholar
  36. Chu, G. and Chang, E. (1988). Xeroderma pigmentosum group E cells lack a nuclear factor that binds to damaged DNA. Science, 242, 564–567Google Scholar
  37. Chu, G. and Chang, E. (1990). Cisplatin-resistant cells express increased levels of a factor that recognizes damaged DNA. Proc. Natl Acad. Sci. USA, 87, 3324–3327PubMedPubMedCentralCrossRefGoogle Scholar
  38. Churchill, M. E. A. and Travers, A. A. (1991). Protein motifs that recognize structural features of DNA. Trends Biochem. Sci., 16, 92–97PubMedCrossRefGoogle Scholar
  39. Ciccarelli, R. B., Solomon, M. J., Varshaysky, A. and Lippard, S. J. (1985). In vivo effects of cis- and trans-diamminedichloroplatinum(II) on SV40 chromosomes: differential repair, DNA-protein cross-linking, and inhibition of replication. Biochemistry, 24, 7533–7540PubMedGoogle Scholar
  40. Claereboudt, J., De Spiegeleer, B., Bruijn, E. A. D., Gijbels, R. and Claeys, M. (1989a). Structural characterization of cisplatin analogues by fast atom bombardment (FAB) and laser microprobe mass spectrometry (LAMMA). J. Pharm. Biomed. Anal., 7, 1599–1610PubMedCrossRefGoogle Scholar
  41. Claereboudt, J., Spiegeleer, B. D., Lippert, B., Bruijn, E. A. D. and Claeys, M. (1989b). Fast atom bombardment and tandem mass spectrometry for the structural characterization of cisplatin analogs and bis-nucleobase adducts with cisplatin. Spectrosc. Int. J., 7, 91–112Google Scholar
  42. Comess, K. M., Burstyn, J. N., Essigmann, J. M. and Lippard, S. J. (1992). Replication inhibition and translesion synthesis on templates containing site-specifically placed cis-diamminedichloroplatinum(II) DNA adducts. Biochemistry, 31, 3975–3990PubMedCrossRefGoogle Scholar
  43. Comess, K. M., Costello, C. E. and Lippard, S. J. (1990). Identification and characterization of a novel linkage isomerization in the reaction of transdiamminedichloroplatinum(II) with d(TCTACGCGTTCT). Biochemistry, 29, 2102–2110PubMedCrossRefGoogle Scholar
  44. Comess, K. M. and Lippard, S. J. (1990). Commentary on: Involvement of protein kinase C in phorbol ester-induced sensitization of HeLa cells to cis-diamminedichloroplatinum(II). Chemtracts: Biochemistry and Molecular Biology, 1, 336–337Google Scholar
  45. Corda, Y., Anin, M.-F., Leng, M. and Job, D. (1992). RNA polymerases react differently at d(ApG) and d(GpG) adducts in DNA modified by cisdiamminedichloroplatinum(II). Biochemistry, 31, 1904–1908PubMedCrossRefGoogle Scholar
  46. Corda, Y., Job, C., Anin, M.-F., Leng, M. and Job, D. (1991). Transcription by eucaryotic and procaryotic RNA polymerases of DNA modified at a d(GG) or a d(AG) site by the antitumor drug cis-diamminedichloroplatinum(II). Biochemistry, 30, 222–230PubMedCrossRefGoogle Scholar
  47. Costello, C.E., Comess, K. M., Plaziak, A. S., Bancroft, D. P. and Lippard, S. J. (1992). Fast atom bombardment and high performance tandem mass spectrometry of platinum(II) oligodeoxyribonucleotide fragments. Int. J. Mass Spectrom. Ion Processes, 122, 255–279CrossRefGoogle Scholar
  48. Dabholkar, M., Parker, R. and Reed, E. (1992). Determinants of cisplatin sensitivity in non-malignant non-drug-selected human T-cell lines. Mutation Res., 274, 45–56PubMedCrossRefGoogle Scholar
  49. deBoer, J. G. and Glickman, B. W. (1989). Sequence specificity of mutation induced by the anti-tumor drug cisplatin in the CHO aprt gene. Carcinogenesis, 10, 1363–1367CrossRefGoogle Scholar
  50. Dedon, P. C. and Borch, R. F. (1987). Characterization of the reactions of platinum antitumor agents with biologic and nonbiologic sulfur-containing nucleophiles. Biochem. Pharmacol., 36, 1955–1964PubMedCrossRefGoogle Scholar
  51. DePamphilis, M. L. (1988). Transcriptional elements as components of eukaryotic origins of DNA replication. Cell, 52, 635–638PubMedCrossRefGoogle Scholar
  52. Dieter, I., Lippert, B. Schöllhom, H. and Thewalt, U. (1990). Coordination chemistry of trans-(NH3)2Pt(II) with uracil nucleobases. A comparison with cis-(NH3)2Pt(II). Z. Naturforsch., 45b, 731–740Google Scholar
  53. Donahue, B. A., Augot, M., Bellon, S. F., Treiber, D. K., Toney, J. H., Lippard, S. J. and Essigmann, J. M. (1990). Characterization of a DNA damage-recognition protein from mammalian cells that binds specifically to intrastrand d(GpG) and d(ApG) DNA adducts of the anticancer drug cisplatin. Biochemistry, 29, 5872–5880PubMedCrossRefGoogle Scholar
  54. Dynan, W. S. and Tjian, R. (1985). Control of eukaryotic messenger RNA synthesis by sequence-specific DNA-binding proteins. Nature, 316, 774–778PubMedCrossRefGoogle Scholar
  55. Eastman, A. (1986). Reevaluation of interaction of cis-dichloro(ethylenediamine)platinum(II) with DNA. Biochemistry, 25, 3912–3915PubMedCrossRefGoogle Scholar
  56. Enns, R. E. and Howell, S. B. (1992). Isolation of a gene associated with resistance to cisplatin. In Howell, S. B. (Ed.), Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Plenum Press, New York, pp. 213–220Google Scholar
  57. Fichtinger-Schepman, A. M. J., Baan, R. A. and Berends, F. (1989a). Influence of the degree of DNA modification on the immunochemical determination of cisplatin-DNA adduct levels. Carcinogenesis, 10, 2367–2369PubMedCrossRefGoogle Scholar
  58. Fichtinger-Schepman, A. M. J., Baan, R. A., Luiten-Schuite, A., van Dijk, M. and Lohman, P. H. M. (1985a). Immunochemical quantitation of adducts induced in DNA by cis-diamminedichloroplatinum(II) and analysis of adduct-related DNA unwinding. Chem. -biol. Interact., 55, 275–288PubMedCrossRefGoogle Scholar
  59. Fichtinger-Schepman, A. M. J., Dijt, F. J., Bedford, P., van Oosterom, A. T., Hill, B. T. and Berends, F. (1988). Induction and removal of cisplatin-DNA adducts in human cells in vivo and in vitro as measured by immunochemical techniques. In Methods for Detecting DNA Damaging Agents in Humans. International Agency for Research on Cancer, pp. 321–328Google Scholar
  60. Fichtinger-Schepman, A. M. J., Lohman, P. H. M. and Reedijk, J. (1982). Detection and quantitation of adducts formed upon reaction of diamminedichloroplatinum(II) with DNA, by anion-exchange chromatography after enzymatic degradation. Nucleic Acids Res., 10, 5345–5356PubMedPubMedCentralCrossRefGoogle Scholar
  61. Fichtinger-Schepman, A., van Oosterom, A. T., Lohman, P. H. M. and Berends, F. (1987). cis-Diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cisdiamminedichloroplatinum(II). Cancer Res., 47, 3000–3004Google Scholar
  62. Fichtinger-Schepman, A. M. J., van der Veer, J. L., den Hartog, J. H. J., Lohamn, P. H. M. and Reedijk, J. (1985b). Adducts of the antitumor drug cisdiamminedichloroplatinum(II) with DNA: Formation, identification, and quantitation. Biochemisty, 24, 707–713CrossRefGoogle Scholar
  63. Fichtinger-Schepman, A. M. J., van der Velde-Visser, S. D., van DijkKnijnenburg, H. C. M., van Oosterom, A. T., Baan, R. A. and Berends, F. (1990). Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: Comparison with in vitro adduct formation. Cancer Res., 50, 7887–7894PubMedGoogle Scholar
  64. Fichtinger-Schepman, A. M. J., Vendrik, C. P. J., van Dijk-Knijneburg, W. C. M., de Jong, W. H., van der Minnen, A. C. E., Claessen, A. M. E., van der Velde-Visser, S. D., de Groot, G., Wubs, K. L., Steerenberg, P. A., Schor-nagel, J. H. and Berends, F. (1989b). Platinum concentrations and DNA adduct levels in tumors and organs of cisplatin-treated LOU/M rats inoculated with cisplatin-sensitive or -resistant immunoglobulin M immunocytoma. Cancer Res., 49, 2862–2867Google Scholar
  65. Filipski, J., Kohn, K. W. and Bonner, W. M. (1983). Differential crosslinking of histones and non-histones in nuclei by cisPt(II). FEBS Lett., 152, 105–108PubMedCrossRefGoogle Scholar
  66. Fok, E. M. (1990). Computation of kinetics of cis-dichlorodiaminoplatinum(II) hydrolysis. Koordinatsionnaya Khimiya, 16, 1554–1559Google Scholar
  67. Forsti, A., Leppala, S., Takala, M., Laatikainen, R. and Hemminki, K. (1989). Kinetics of reaction of cis-diamminedichloroplatinum(II) with DNA. Pharmacol. Toxicol., 64, 120–125PubMedCrossRefGoogle Scholar
  68. Fox, E. P. and Loehrer, P. J. (1991). Chemotherapy for advanced testicular cancer. Hematology/Oncology Clinics of North America, 5, 1173–1187PubMedGoogle Scholar
  69. Frommer, G. and Lippert, B. (1990). Head-tail oriented nucleobases (B = guanine, cytosine) in cis-A2PtB2 resisting cyanide substitution. Implications for the nature of strongly DNA-bound cisplatin. Inorg. Chem., 29, 3259–3260CrossRefGoogle Scholar
  70. Ganeva, R. L., Spassovska, N. C. and Genchev, D. D. (1990). The effect of some platinum compounds on the biosynthesis of RNA and its precursors. J. Inorg. Biochem., 40, 13–18PubMedCrossRefGoogle Scholar
  71. Gibbons, G. R., Kaufmann, W. K. and Chaney, S. G. (1991). Role of DNA replication in carrier-ligand-specific resistance to platinum compounds in L1210 cells. Carcinogenesis, 12, 2253–2257PubMedCrossRefGoogle Scholar
  72. Godwin, A. K., Meister, A., Odwyer, P. J., Huang, C. S., Hamilton, T. C. and Anderson, M. E. (1992). High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc. Natl Acad. Sci. USA, 89, 3070–3074PubMedPubMedCentralCrossRefGoogle Scholar
  73. Gralla, J. D., Sasse-Dwight, S. and Poljak, L. G. (1987). Formation of blocking lesions at identical DNA sequences by the nitrosourea and platinum classes of anticancer drugs. Cancer Res., 47, 5092–5096PubMedGoogle Scholar
  74. Green, M. and Miller, J. M. (1987). A cyclic nucleobase phosphate: Fast atom bombardment studies on a 1: 1 mixture of cis-[Pt(NH3)2(OH)21(CF3SO3)2 and guanosine 5’-monophosphoric acid. J. Chem. Soc., Chem. Commun., 1864–1865Google Scholar
  75. Greene, M. H. (1992). Is cisplatin a human carcinogen. J. Nat! Cancer Inst., 84, 306–312PubMedCrossRefGoogle Scholar
  76. Haneda, H., Katabami, M., Miyamoto, H., Isobe, H., Shimizu, T., Ishiguro, A., Moriuti, T., Takasaki, Y. and Kawakami, Y. (1991). The relationship of the proliferating cell nuclear antigen protein to cis-DDP resistance of a murine leukemia cell line P388/CDDP. Oncology, 48, 234–238PubMedCrossRefGoogle Scholar
  77. Hansson, J. and Wood, R. D. (1989). Repair synthesis by human cell extracts in DNA damaged by cis- and trans-diamminedichloroplatinum(H). Nucleic Acids Res., 17, 8073–8091PubMedPubMedCentralCrossRefGoogle Scholar
  78. Harder, H. C. and Rosenberg, B. (1970). Inhibitory effects of antitumor platinum compounds on DNA, RNA and protein synthesis in mammalian cells in vitro. Int. J. Cancer, 6, 207–216PubMedCrossRefGoogle Scholar
  79. Harrison, S. C. (1991). A structural taxonomy of DNA-binding domains. Nature, 353, 715–719PubMedCrossRefGoogle Scholar
  80. Heiger-Bemays, W. J., Essigmann, J. M. and Lippard, S. J. (1990). Effect of the antitumor drug cis-diamminedichloroplatinum(II) and related platinum complexes on eukaryotic DNA replication. Biochemistry, 29, 8461–8466CrossRefGoogle Scholar
  81. Hemminiki, K. and Thilly, W. G. (1988). Binding of cisplatin to specific sequences of human DNA in vitro. Mutation Res., 202, 133–138CrossRefGoogle Scholar
  82. Hoffmann, J.-S., Hubscher, U., Michot, B. and Villani, G. (1991). Interaction of cis-diamminedichloroplatinum(II) with single-stranded DNA in the presence or absence of Escherichia coli single-stranded binding protein. Biochem. Pharma-col., 42, 1393–1398CrossRefGoogle Scholar
  83. Hoffmann, J.-S., Johnson, N. P. and Villani, G. (1989). Conversion of monofunctional DNA adducts of cis-diamminedichloroplatinum(II) to bifunctional lesions. J. Biol. Chem., 264, 15130–15135PubMedGoogle Scholar
  84. Hollander, M. C. and Fornace, A. J., Jr. (1989). Induction of fos RNA by DNA-damaging agents. Cancer Res., 49, 1687–1692PubMedGoogle Scholar
  85. Howe-Grant, M. and Lippard, S. J. (1980). Aqueous platinum(II) chemistry; Binding to biological molecules. Metal Ions Biol. Syst., 11, 63–125Google Scholar
  86. Howell, S. B., Pfeifle, C. E., Wing, W. E. and Olshen, R. A. (1983). Intraperitoneal cis-diamminedichloroplatinum(II) with systemic thiosulfate protection. Cancer Res., 43, 1426–1431PubMedGoogle Scholar
  87. Howle, J. A. and Gale, G. R. (1970). cis-DDP: Persistent and selective inhibition of deoxyribonucleic acid synthesis in vivo. Biochem. Pharmacol. 19 2757–2762PubMedCrossRefGoogle Scholar
  88. Iakovidis, A., Hadjiliadis, N., Dahan, F., Laussac, J.-P. and Lippert, B. (1990). Complete displacement of N,O bound amino acids (amacH) in cis-[(NH3)2Pt(amac)]NO3 chelates by 9-methylguanine (9-MeGH) and 9-methyladenine (9-MeA). The crystal structure of cis-[(NH3)2Pt(9-MeA-N7)2](NO3)2.1.5 H2O. Inorg. Chim. Acta, 175, 57–63CrossRefGoogle Scholar
  89. Inagaki, K., Alink, M., Nagai, A., Kidani, Y. and Reedijk, J. (1990). Unusual isomerization reaction of a platinum-dinucleotide compound. Inorg. Chem., 29, 2183–2185CrossRefGoogle Scholar
  90. Inagaki, K., Tomita, A. and Kidani, Y. (1988). Studies on the reaction products of antitumor platinum complexes with d(ApG), d(GpA) and d(pGpA). 2’-Deoxy sugar is favorable for G-N7, A-N1 chelation. Bull. Chem. Soc. Jpn, 61, 2825–2831CrossRefGoogle Scholar
  91. Isonishi, S., Andrews, P. and Howell, S. (1990). Increased sensitivity to cisdiamminedichloroplatinum(II) in human ovarian carcinoma cells in response to treatment with 12-O-Tetradecanoylphorbol 13-acetate. J. Biol. Chem., 265, 3623–3627PubMedGoogle Scholar
  92. Isonishi, S., Hom, D. K., Thiebaut, F. B., Mann, S. C., Andrews, P. A., Basu, A., Lazo, J. S., Eastman, A. and Howell, S. B. (1991). Expression of the c-Ha-ras oncogene in mouse NIH-3T3 cells induces resistance to cisplatin. Cancer Res., 51, 5903–5909PubMedGoogle Scholar
  93. Jäckel, M. and Köpf-Maier, P. (1991). Influence of cisplatin on cell-cycle progression in xenografted human head and neck carcinomas. Cancer Chemother. Pharmacol., 27, 464–471PubMedCrossRefGoogle Scholar
  94. Johnson, N. P., Hoeschele, J. D., Rahn, R. O., O’Neill, J. P. and Hsie, A. W. (1980). Mutagenicity, cytotoxicity, and DNA binding of platinum(II) chloro-amines in Chinese hamster ovary cells. Cancer Res., 40, 1463–1468PubMedGoogle Scholar
  95. Johnson, N. P., Macquet, J. P., Wiebers, J. L. and Monsarrat, B. (1982). Structures of the adducts formed between [Pt(dien)Cl]Cl and DNA in vitro. Nucleic Acids Res., 10, 5255–5271PubMedCrossRefGoogle Scholar
  96. Johnson, N. P., Mazard, A. M., Escalier, J. and Macquet, J. P. (1985). Mechanism of the reaction between cis-[PtC12(NH3)2] and DNA in vitro. J. Am. Chem. Soc., 107, 6376–6380CrossRefGoogle Scholar
  97. Jones, J. C., Zhen, W., Reed, E., Parker, R. J., Sancar, A. and Bohr, V. A. (1991). Gene-specific formation and repair of cisplatin intrastrand adducts and intrastrand cross-links in Chinese hamster ovary cells. J. Biol. Chem., 266, 7101–7107PubMedGoogle Scholar
  98. Jones, M. M. and Beaty, J. A. (1991). Rate of displacement of guanosine by cyanide from cis-diamminebis(guanosine)platinum(II) chloride determined by using 13C NMR. Inorg. Chem., 30, 1584–1587CrossRefGoogle Scholar
  99. Kashani-Sabet, M., Wang, W. and Scanlon, K. J. (1990). Cyclosporin A suppresses cisplatin-induced c-fos gene expression in ovarian carcinoma cells. J. Biol. Chem., 265, 11285–11288PubMedGoogle Scholar
  100. Kasselouri, S., Laussac, J.-P. and Hadjiliadis, N. (1989). trans-Ternary complexes of Pd(II) with nucleosides and dipeptides. Models for trans-DDP-DNA-protein crosslinks. Inorg. Chim. Acta, 166, 239–248CrossRefGoogle Scholar
  101. Kawai, K., Kamatani, N., Georges, E. and Ling, V. (1990). Identification of a membrane glycoprotein overexpressed in murine lymphoma sublines resistant to cis-diamminedichloroplatinum(II). J. Biol. Chem., 265, 13137–13142PubMedGoogle Scholar
  102. Keck, M. V. and Lippard, S. J. (1992). Unwinding of supercoiled DNA by platinum-ethidium and related complexes. J. Am. Chem. Soc., 114, 3386–3390CrossRefGoogle Scholar
  103. Kelland, L. R., Mistry, P., Abel, G., Freidlos, F., Loh, S. Y., Roberts, J. J. and Harrap, K. R. (1992). Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminatous germ cell line. Cancer Res., 52, 1710–1716PubMedGoogle Scholar
  104. Kelley, S. and Rozencweig, M. (1989). Resistance to platinum compounds: Mechanisms and beyond. Eur. J. Cancer Clin. Oncol., 25, 1135–1140PubMedCrossRefGoogle Scholar
  105. Kelley, S. L., Basu, A., Teicher, B. A., Hacker, M. P., Hamer, D. H. and Lazo, J. S. (1988). Overexpression of metallothionein confers resistance to anticancer drugs. Science, 241, 1813–1815PubMedCrossRefGoogle Scholar
  106. Kline, T. P., Marzilli, L. G., Live, D. and Zon, G. (1989). Investigations of platinum amine induced distortions in single- and double-stranded oligodeoxyribonucleotides. J. Am. Chem. Soc., 111, 7057–7068CrossRefGoogle Scholar
  107. Krizanovic, O., Pesch, F. J. and Lippert, B. (1989). Nucleobase displacement from trans-diamine-platinum(II) complexes. A rationale for the inactivity of transDDP as an antitumor agent? Inorg. Chim. Acta, 165, 145–146CrossRefGoogle Scholar
  108. Langford, C. H. and Gray, H. B. (1965). Ligand Substitution Processes. W. A. Benjamin, New YorkGoogle Scholar
  109. Lemaire, M.-A., Schwartz, A., Rahmouni, A. R. and Leng, M. (1991). Interstrand crosslinks are preferentially formed at the d(GC) sites in the reaction between cis-diamminedichloroplatinum(II) and DNA. Proc. Natl Acad. Sci. USA, 88, 1982–1985PubMedPubMedCentralCrossRefGoogle Scholar
  110. Lempers, E. L. M. and Reedijk, J. (1990a). Characterization of products from [PtCI(dien)]CI and S-adenosyl-L-homocysteine. Evidence for a pH-dependent migration of the platinum moiety from the sulfur atom to the amine group and vice versa. Inorg. Chem., 29, 1880–1884CrossRefGoogle Scholar
  111. Lempers, E. L. M. and Reedijk, J. (1990b). Reversibility of binding of cisplatin-methionine in proteins by diethyldithiocarbamate or thiourea: A study with model adducts. Inorg. Chem., 29, 217–222CrossRefGoogle Scholar
  112. Leopold, W. R., Miller, E. C. and Miller, J. A. (1979). Carcinogenicity of antitumor cis-platinum(II) coordination complexes in the mouse and rat. Cancer Res., 39, 913–918PubMedGoogle Scholar
  113. Lepre, C. A., Chassot, L., Costello, C. E. and Lippard, S. J. (1990). Synthesis and characterization of trans-[Pt(NH3)2C12] adducts of d(CCTCGAGTCTCC).d(GGAGACTCGAGG). Biochemistry, 29, 811–823PubMedCrossRefGoogle Scholar
  114. Lim, M. C. and Martin, R. B. (1976). Nature of cis-amine Pd(II) and antitumor cis-amine Pt(II) complexes in aqueous solutions. J. Inorg. Nucl. Chem., 38, 1911–1914CrossRefGoogle Scholar
  115. Lippard, S. J. and Hoeschele, J. D. (1979). Binding of cis- and transdichlorodiammineplatinum(II) to the nucleosome core. Proc. Natl Acad. Sci. USA, 76, 6091–6095PubMedPubMedCentralCrossRefGoogle Scholar
  116. Lippert, B. (1989). Platinum nucleobase chemistry. Prog. Inorg. Chem., 37, 1–97CrossRefGoogle Scholar
  117. Litterst, C. L. (1984). In Hacker, M. P., Douple, E. B. and Krakoff, I. H. (Eds), Platinum Coordination Complexes in Cancer Chemotherapy. Martinus Nijhoff, Dordrecht, p. 78Google Scholar
  118. Litterst, C. L., Gram, T. E., Dedrich, R. L., Leroy, A. F. and Guarino, A. M. (1976). Distribution and disposition of platinum following intravenous administration of cis-diamminedichloroplatinum(II) to dogs. Cancer Res., 36, 2340–2344PubMedGoogle Scholar
  119. Litterst, C. L., LeRoy, A. F. and Guarino, A. M. (1979). Disposition and distribution of platinum following parenteral administration of cis-dichlorodi-ammineplatinum(II) to animals. Cancer Treat. Rep., 63, 1485–1492PubMedGoogle Scholar
  120. Loehrer, P. J. and Einhorn, L. H. (1984). Cisplatin. Ann. Intern. Med., 100, 704–713PubMedCrossRefGoogle Scholar
  121. McCloskey, J. A. (1982). In Alderweireldt, F. C. and Esmans, E. L. (Eds), Nucleosides, Nucleotides, and Their Biological Applications. University of Antwerp, Belgium, pp. 47–67Google Scholar
  122. May, A., Nairn, R. S., Okumoto, D. S., Wassermann, K., Stevnsner, T., Jones, J. C. and Bohr, V. A. (1993). Repair of individual DNA strands in the hamster dihydrofolate reductase gene after treatment with ultraviolet light, alkylating agents, and cisplatin. J. Biol. Chem., 268, 1650–1657PubMedGoogle Scholar
  123. Malinge, J.-M., Schwartz, A. and Leng, M. (1987). Characterization of the ternary complexes formed in the reaction of cis-diamminedichloroplatinum(II), ethidium bromide and nucleic acids. Nucleic Acids Res., 15, 1779–1797PubMedPubMedCentralCrossRefGoogle Scholar
  124. Marrot, L. and Leng, M. (1989). Chemical probes of the conformation of DNA modified by cis-diamminedichloroplatinum(II). Biochemistry, 28, 1454–1461PubMedCrossRefGoogle Scholar
  125. Martin, L. B., III, Schreiner, A. F. and van Breemen, R. B. (1991). Characterization of cisplatin adducts of oligonucleotides by fast atom bombardment mass spectrometry. Anal. Biochem., 193, 6–15Google Scholar
  126. Masuda, H., Tanaka, T., Matsuda, H. and Kusaba, I. (1990). Increased removal of DNA-Marilyn platinum in a human ovarian cancer cell line resistant to cisdiamminedichloroplatinum(II). Cancer Res., 50, 1863–1866PubMedGoogle Scholar
  127. Mellon, I. M. and Hanawalt, P. C. (1989). Induction of the Eschericia coli lactose operon selectively increases repair of its transcribed DNA strand. Nature, 342, 95–98PubMedCrossRefGoogle Scholar
  128. Mellon, I. M., Spivak, G. S. and Hanawalt, P. C. (1987). Selective removal of transcription-blocking DNA damage from the transcribed strand of the mammalian DHFR gene. Cell, 51, 241–249PubMedCrossRefGoogle Scholar
  129. Millar, D. P., Ho, K. M. and Aroney, M. J. (1988). Modification of DNA dynamics by platinum drug binding: A time-dependent fluorescence depolarization study of the interaction of cis- and trans-diamminedichloroplatinum(II) with DNA. Biochemistry, 27, 8599–8606PubMedCrossRefGoogle Scholar
  130. Miller, C. A., III, Cohen, M. D. and Costa, M. (1991). Complexing of actin and other nuclear proteins to DNA by cis-diamminedichloroplatinum(II) and chromium compounds. Carcinogenesis, 12, 269–276PubMedCrossRefGoogle Scholar
  131. Miller, S. E. and House, D. A. (1989a). The hydrolysis products of cisdiamminedichloroplatinum(II). 1. The kinetics of formation and anation of the cis-diammine(aqua)chloroplatinum(II) cation in acidic aqueous solution. Inorg. Chim. Acta, 161, 131–137CrossRefGoogle Scholar
  132. Miller, S. E. and House, D. A. (1989b). The hydrolysis products of cisdichlorodiammineplatinum(II). 2. The kinetics of formation and anation of the cis-diamminedi(aqua)platinum(II) cation. Inorg. Chim. Acta, 166, 189–197CrossRefGoogle Scholar
  133. Miller, S. E. and House, D. A. (1990). The hydrolysis products of cisdichlorodiammineplatinum(II). 3. Hydrolysis kinetics at physiological pH. Inorg. Chim. Acta, 173, 53–60CrossRefGoogle Scholar
  134. Mis, J. R. A. and Kunz, B. A. (1990). Analysis of mutations induced in the SUP4-o gene of Saccharomyces cerevisiae by cis-diammine dichloroplatinum(II). Carcinogenesis, 11, 633–638PubMedCrossRefGoogle Scholar
  135. Miyazaki, M., Kohno, K., Saburi, Y., Matsuo, K., Ono, M., Kuwano, M., Tsuchida, S., Sato, K., Sakai, M. and Muramatsu, M. (1990). Drug resistance to cis-diamminedichloroplatinum(II) in Chinese hamster ovary cell lines transfected with glutathione S-transferase PI gene. Biochem. Biophys. Res. Commun., 166, 1358–1364PubMedCrossRefGoogle Scholar
  136. Mukundan, S., Jr., Xu, Y., Zon, G. and Marzilli, L. G. (1991). Heteronuclear 13C–1H NMR investigation of the effects on an oligodeoxyribonucleotide of intrastrand crosslinking by a Pt anticancer drug. A large shift of C3’ accompanies an S to N conformation change. J. Am. Chem. Soc., 113, 3021–3027CrossRefGoogle Scholar
  137. Naser, L. J., Pinto, A. L., Lippard, S. J. and Essigmann, J. M. (1988). Chemical and biological studies of the major DNA adduct of cis-diamminedichloroplatinum(II), cis-[Pt(NH3)2{d(GpG)}], built into a specific site in a viral genome. Biochemistry, 27, 4357–4367.PubMedCrossRefGoogle Scholar
  138. Ogawa, M., Gale, G. R. and Keim, S. S. (1975). Effects of cis-diamminedichloroplatinum (NSC 119875) on murine and human hemopoietic precursor cells. Cancer Res., 35, 1398–1401PubMedGoogle Scholar
  139. Page, J. D., Husain, I., Sancar, A. and Chaney, S. G. (1990). Effect of the diaminocyclohexane carrier ligand on platinum adduct formation, repair, and lethality. Biochemistry, 29, 1016–1024PubMedCrossRefGoogle Scholar
  140. Parker, R. J., Gill, I., Tarone, R., Vionnet, J. A., Grunberg, S., Muggia, F. M. and Reed, E. (1991). Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry. Carcinogenesis, 12, 1253–1258Google Scholar
  141. Patel D. J. (1992). Covalent carcinogenic guanine-modified DNA lesions: Solution structures of adducts and crosslinks. Current Opinion Struct. Biol., 2, 345–353CrossRefGoogle Scholar
  142. Patton, T. F., Himmelstein, K. J., Belt, R., Bannister, S. J., Sternson, L. A. and Repta, A. J. (1978). Plasma levels and urinary excretion of filterable platinum species following bolus injection and iv infusion of cis-dichlorodiammineplatinum(II) in Man. Cancer Treat. Rep., 62, 1359–1362PubMedGoogle Scholar
  143. Peerey, L. M. and Kostic, N. M. (1987). Transition-metal compounds as new reagents for selective cross-linking of proteins. Synthesis and characterization of 2 bis(cytochrome c) complexes of platinum. Inorg. Chem., 26, 2079–2083CrossRefGoogle Scholar
  144. Pesch, F. J., Preut, H. and Lippert, B. (1990). Mixed nucleobase, amino acid complexes of Pt(II). Preparation and X-ray structure of trans-[(CH3NH2)2Pt(1MeC-N 3)(gly-N)]NO3.2H2O and its precursor trans-[(CH3NH2)2Pt(1-MeC-N 3)Cl]Cl•H2O. Inorg. Chim. Acta, 169, 195–200CrossRefGoogle Scholar
  145. Pil, P. M. and Lippard, S. J. (1992). Specific binding of chromosomal protein HMG 1 to DNA damaged by the anticancer drug cisplatin. Science, 256, 234–237PubMedCrossRefGoogle Scholar
  146. Pinto, A. L. and Lippard, S. J. (1985a). Binding of the antitumor drug cisdiamminedichloroplatinum(II) (cisplatin) to DNA. Biochem. Biophys. Acta, 780, 167–180PubMedGoogle Scholar
  147. Pinto, A. L. and Lippard, S. J. (1985b). Sequence-dependent termination of in vitro DNA synthesis by cis- and trans-diamminedichloroplatinum(II). Proc. Natl Acad. Sci. USA, 82, 4616–4619PubMedPubMedCentralCrossRefGoogle Scholar
  148. Pinto, A. L., Naser, L. J., Essigmann, J. M. and Lippard, S. J. (1986). Site-specifically platinated DNA, a new probe of the biological activity of platinum anticancer drugs. J. Am. Chem. Soc., 108, 7405CrossRefGoogle Scholar
  149. Pizzo, S. V., Roche, P. A., Feldman, S. R. and Gonias, S. L. (1986). Further characterization of the platinum-reactive component of the a2-macroglobulinreceptor recognition site. Biochem. J., 238, 217–225PubMedPubMedCentralCrossRefGoogle Scholar
  150. Pizzo, S. V., Swaim, M. W., Roche, P. A. and Gonias, S. L. (1988). Selectivity and stereospecificity of the reactions of dichlorodiammineplatinum(II) with three purified plasma proteins. J. Inorg. Biochem., 33, 67–76PubMedCrossRefGoogle Scholar
  151. Plaziak, A. S., Costello, C. E., Comess, K. M., Bancroft, D. P. and Lippard, S. J. (1990). High performance tandem mass spectrometry of platinated oligonucleotide fragments. In Proceedings of the 38th ASMS Conference on Mass Spectrometry and Allied Topics, Tucson, Arizona, pp. 792–793Google Scholar
  152. Plooy, A. C. M., van Dijk, M. and Lohman, P. H. M. (1984). Induction and repair of DNA cross-links in Chinese hamster ovary cells treated with various platinum coordination compounds in relation to platinum binding to DNA, cytotoxicity, mutagenicity, and antitumor activity. Cancer Res., 44, 2043–2051PubMedGoogle Scholar
  153. Poirier, M. C., Egorin, M. J., Fichtinger-Schepman, A. M. J., Yuspa, S. H. and Reed, E. (1988). DNA adducts of cisplatin and carboplatin in tissues of cancer patients. In Bartsch, H., Hemminki, K. and O’Neil, I. K. (Eds), Methods for Detecting DNA Damaging Agents in Humans: Applications in Cancer Epidemiology and Prevention. IARC Scientific Publications, Lyon, pp. 313–320Google Scholar
  154. Poirier, M. C., Reed, E., Litterst, C. L., Katz, D. and Guptaburt, S. (1992). Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients. Cancer Res., 52, 149–153PubMedGoogle Scholar
  155. Popoff, S. C., Beck, D. J. and Rupp, W. D. (1987). Repair of plasmid DNA damaged in vitro with cis- or trans-diamminedichloroplatinum(II) in Escherichia coli. Mutation Res., 183, 129–137PubMedGoogle Scholar
  156. Ptak, M., Rahmouni, A., Mazeau, K., Thuong, N. T. and Leng, M. (1989). Structure of the intrastrand cis-[Pt(NH3)2{d(GpCpG)}] adduct in a dodecanucleotide duplex I. A 1H and 31P n.m.r. study. Anti-cancer Drug Design, 4, 53–61PubMedGoogle Scholar
  157. Ratilla, E. M. A., Scott, B. K., Moxness, M. S. and Kostic, N. M. (1990). Terminal and new bridging coordination of methylguanidine, arginine, and canavanine to platinum(II). The first crystallographic study of bonding between a transition metal and a guanidine ligand. Inorg. Chem., 29, 918–926CrossRefGoogle Scholar
  158. Roberts, J. J. and Friedlos, F. (1987). Differential toxicity of cis- and transdiamminedichloroplatinum(II) toward mammalian cells: Lack of any difference in the rates of loss of their DNA-bound adducts. Cancer Res., 47, 31–36PubMedGoogle Scholar
  159. Robichaud, A., Mehra, M.-C., Jankowski, C., Virelizier, H., Butour, J.-L. and Johnson, N. P. (1989). Study of platination of nucleic acids using atomic absorption and mass spectrometry. Spectroscopy Lett., 22, 59–68CrossRefGoogle Scholar
  160. Roos, I. A. G., Thomson, A. J. and Eagles, J. (1974). Mass spectrometric studies of the interaction of platinum complexes with nucleoside analogues. Chem.-biol. Interact., 8, 421–427PubMedCrossRefGoogle Scholar
  161. Rosenberg, B., Van Camp, L. and Krigas, T. (1965). Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature, 205 698PubMedCrossRefGoogle Scholar
  162. Royer-Pokora, B., Gordon, L. K. and Haseltine, W. A. (1981). Use of exonuclease III to determine the site of stable lesions in defined sequences of DNA: the cyclobutane pyrimidine dimer and cis- and trans-dichlorodiammineplatinum(II) examples. Nucleic Acids Res., 9, 4595–4609PubMedPubMedCentralCrossRefGoogle Scholar
  163. Sancar, A. and Sancar, G. B. (1988). DNA repair enzymes. Ann. Rev. Biochem., 57, 29–67PubMedCrossRefGoogle Scholar
  164. Santos, R. A., Tang, P. and Harbison, G. S. (1989). Determination of the DNA sugar pucker using 13C NMR spectroscopy. Biochemistry, 28, 9372–9378PubMedCrossRefGoogle Scholar
  165. Schilder, R., Hall, L., Monks, A., Handel, L., Fornace, A., Jr., Ozols, R., Fojo, A. and Hamilton, T. C. (1990). Metallothionein gene expression and resistance to cisplatin in human ovarian cancer. Int. J. Cancer, 45, 416–422PubMedCrossRefGoogle Scholar
  166. Schwarts, A., Marrot, L. and Leng, M. (1989). Conformation of DNA modified at a d(GG) or a d(AG) site by the antitumor drug cis-diamminedichloroplatinum(II). Biochemistry, 28, 7975–7979CrossRefGoogle Scholar
  167. Schwartz, A., Marrot, L. and Leng, M. (1989). Conformation of DNA modified at a d(GG) or a d(AG) site by the antitumor drug cis-diamminedichloroplatinum(II). Biochemistry, 28, 7975–7979PubMedCrossRefGoogle Scholar
  168. Selby, C. P. and Sancar, A. (1990). Transcription preferentially inhibits nucleotide excision repair of the template DNA strand in vitro. J. Biol. Chem., 265, 21330–21336PubMedGoogle Scholar
  169. Selby, C. P. and Sancar, A. (1991). Gene- and strand-specific repair in vitro: Partial purification of a transcription-repair coupling factor. Proc. Natl Acad. Sci. USA, 88, 8232–8236PubMedPubMedCentralCrossRefGoogle Scholar
  170. Shellard, S. A., Hosking, L. K. and Hill, B. T. (1991). Anomalous relationship between cisplatin sensitivity and the formation and removal of platinum-DNA adducts in two human ovarian carcinoma cell lines in vitro. Cancer Res., 51, 4557–4564PubMedGoogle Scholar
  171. Sherman, S. E. and Lippard, S. J. (1987). Structural aspects of platinum anticancer drug interactions with DNA. Chem. Rev., 87, 1153–1181CrossRefGoogle Scholar
  172. Sip, M., Schwartz, A., Voyelle, F., Ptak, M. and Leng, M. (1992). Distortions induced in DNA by cis-platinum interstrand adducts. Biochemistry, 31, 2508–2513PubMedCrossRefGoogle Scholar
  173. Struik, A. F., Zuiderwijk, C. T. M., Vanboom, J. H., Elding, L. I. and Reedijk, J. (1991). Guanine-06 methylation reduces the reactivity of d(GpG) toward platinum complexes. J. Inorg. Biochem., 44, 249–260PubMedCrossRefGoogle Scholar
  174. Szymkowski, D. E., Yarema, K., Essigmann, J. M., Lippard, S. J. and Wood, R. D. (1993). An intrastrand d(GpG) platinum crosslink in duplex M13 DNA is refractory to repair by human cell extracts. Proc. Natl Acad. Sci. USA, 89, 10772–10776CrossRefGoogle Scholar
  175. Taylor, J. and O’Day, C. L. (1990). cis-syn Thymine dimers are not absolute blocks to replication by DNA polymerase I of Escherichia coli in vitro. Biochemistry 29,1624–1632Google Scholar
  176. Teicher, B. A., Herman, T. S., Holden, S. A., Wang, Y., Pfeffer, M. R., Crawford, J. W. and Frei, E., III (1990). Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science, 247, 1457–1462PubMedGoogle Scholar
  177. Terheggen, P. M. A. B., Emondt, J. Y., Root, B. G. J., Schrier, P. I., Den Engelse, L. and Begg, A. C. (1990). Correlation between cell killing by cisdiamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum. Cancer Res., 50, 3556–3561PubMedGoogle Scholar
  178. Terheggen, P. M. A. B., Root, B. G. J., Lempers, E. L. M., van Tellingen, O., Begg, A. C. and den Engelse, L. (1991). Antibodies against cisplatin-modified DNA and cisplatin-modified (di)nucleotides. Cancer Chemother. Pharmacol., 28, 185–191PubMedCrossRefGoogle Scholar
  179. Terleth, C., van de Putte, P. and Brouwer, J. (1991). New Insights in DNA Repair: Preferential Repair of Transcriptionally Active DNA. Mutagenesis, 6, 103–111PubMedCrossRefGoogle Scholar
  180. Tilby, M. J., Johnson, C., Knox, R. J., Cordell, J., Roberts, J. J. and Dean, C. J. (1991). Sensitive detection of DNA modifications induced by cisplatin and carboplatin in vitro and in vivo using a monoclonal antibody. Cancer Res., 51, 123–129PubMedGoogle Scholar
  181. Toney, J. H., Donahue, B. A., Kellett, P. J., Bruhn, S. L., Essigmann, J. M. and Lippard, S. J. (1989). Isolation of cDNAs encoding a human protein that binds selectively to DNA modified by the anticancer drug cis-diamminedichloroplatinum(II). Proc. Natl Acad. Sci. USA, 86, 8328–8332PubMedPubMedCentralCrossRefGoogle Scholar
  182. Tullius, T. D. and Lippard, S. J. (1981). cis-Diamminedichloroplatinum(II) binds in a unique manner to oligo(dG)-Oligo(dC) sequences in DNA — A new assay using exonuclease III. J. Am. Chem. Soc., 103, 4620–4622Google Scholar
  183. Tullius, T. D. and Lippard, S. J. (1982). Ethidium bromide changes the nuclease-sensitive DNA binding sites of the antitumor drug cis-diamminedichloroplatinum(II). Proc. Natl Acad. Sci. USA, 79, 3489–3492PubMedPubMedCentralCrossRefGoogle Scholar
  184. Urata, H. and Akagi, M. (1989). Mechanism of the reversal reaction of platinated DNA with thiourea studied by platinated 5’-GMP. Biochem. Biophys. Res. Commun., 161, 819–824PubMedCrossRefGoogle Scholar
  185. Urata, H., Fujikawa, K., Tamura, M. and Akagi, M. (1990). Stability of platinated oligonucleotide duplexes containing a base pair mismatch at the site complementary to the platination site. J. Am. Chem. Soc., 112, 8611–8612CrossRefGoogle Scholar
  186. Urata, H., Ueno, M., Yamasaki, F. and Akagi, M. (1991). Interstrand crosslinking of the hexadeoxynucleotide d(TACGTA) upon reaction with transdiamminedichloroplatinum(II). Biochem. Biophys. Res. Commun., 175, 537–542PubMedCrossRefGoogle Scholar
  187. van Garderen, C. J., Altona, C. and Reedijk, J. (1988). Alterations in the d(CpGpT) structure in solution as a result of [platinum chloro(diethylenetriamine]+ binding. Eur. J. Biochem., 178, 115–121PubMedCrossRefGoogle Scholar
  188. van Garderen, C. J., Altona, C. and Reedijk, J. (1990). Conformational changes in a single- and double-stranded nonanucleotide upon complexation of a monofunctional platinum compound as studied by 111 NMR, 31P NMR, and CD methods. Inorg. Chem., 29, 1481–1487CrossRefGoogle Scholar
  189. van Garderen, C. J., Bloemink, M. J., Richardson, E. and Reedijk, J. (1991). Formation and structure of the reaction products of PtC12(en) with d(pGpG) and d(GpG); preference for d(GpG) chelation after phosphate dehydronation. J. Inorg. Biochem., 42, 199–205CrossRefGoogle Scholar
  190. van Garderen, C. J., van den Elst, H., van Boom, J. H., Reedijk, J. and van Houte, L. P. A. (1989). A double-stranded DNA fragment shows a significant decrease in double-helix stability after binding of monofunctional platinum amine compounds. J. Am. Chem. Soc., 111, 4123–4125CrossRefGoogle Scholar
  191. Villani, G., Hübscher, U. and Butour, J. L. (1988). Sites of termination of in vitro DNA synthesis on cis-diamminedichloroplatinum(II) treated single-stranded DNA: A comparison between E. coli DNA polymerase I and eucaryotic DNA polymerase a. Nucleic Acid Res., 16, 4407–4418PubMedPubMedCentralCrossRefGoogle Scholar
  192. Visse, R., de Ruijter, M. Brouwer, J., Brandsma, J. A. and van de Putte, P. (1991). uvr Excision repair protein complex of Eschericia coli binds to the convex side of a cisplatin-induced kink in the DNA. J. Biol. Chem., 266, 7609–7617Google Scholar
  193. Vrieling, H., van Rooijen, M. L., Groen, N. A., Zdzienicka, Z., Simons, J. W. I. M., Lohman, P. H. M., and van Zeeland, A. A. (1989). DNA Strand Specificity for UV-induced Mutations in Mammalian Cells. Mol. Cell. Biol., 9, 1277–1283PubMedPubMedCentralCrossRefGoogle Scholar
  194. Walker, G. C. (1984). Mutagenesis and inducible responses to deoxyribonucleic acid damage in Escherichia coli. Microbiol. Rev., 48, 60–93PubMedGoogle Scholar

Copyright information

© The contributors 1993

Authors and Affiliations

  • Kenneth M. Comess
  • Stephen J. Lippard

There are no affiliations available

Personalised recommendations